We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval
Read MoreHide Full Article
Swiss pharma giant Novartis AG (NVS - Free Report) announced that the FDA approved its ophthalmology drug Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD).
Per the company, Beovu is the first FDA approved anti-VEGF to offer greater fluid resolution as compared to Regeneron (REGN - Free Report) and Bayer’s (BAYRY - Free Report) market-leading drug Eylea as well as the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.
The FDA approval was based on encouraging data from the phase III HAWK and HARRIER clinical trials, in which Beovu demonstrated non-inferiority compared to Eylea in mean change in best-corrected visual acuity (BCVA) at year one (week 48). Beovu also demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the retina) as early as week 16 and at one year versus Eylea.
Data from both trials showed that at year one, more than half of patients were maintained on the three-month dosing interval (56% in HAWK and 51% in HARRIER).
Novartis’ shares have lost 0.5% in the year so far, in line with the industry’s decline.
Wet AMD is a leading cause of blindness, affecting more than 20 million people worldwide. However, frequent injections are a common reason, due to which patients drop out of the treatment.
Beovu is expected to pose stiff competition to Eylea as it is the first drug to offer less frequent dosing in the first year of therapy while maintaining its effectiveness. The drug’s potential to treat patients with quarterly injections is a major positive and should enable it to capture market share.
The FDA approval of Beovu will strengthen Novartis’ ophthalmology franchise, which comprises Lucentis.
We note that Lucentis is also approved for wet AMD along with macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME), among others.
Novartis has a collaboration agreement with Roche (RHHBY - Free Report) for Lucentis. Roche retains commercial rights for the drug in the United States while Novartis has exclusive commercial rights for the rest of the world.
Approval of new drugs bodes well for Novartis as it looks to strengthen its core pharmaceutical business.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval
Swiss pharma giant Novartis AG (NVS - Free Report) announced that the FDA approved its ophthalmology drug Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD).
Per the company, Beovu is the first FDA approved anti-VEGF to offer greater fluid resolution as compared to Regeneron (REGN - Free Report) and Bayer’s (BAYRY - Free Report) market-leading drug Eylea as well as the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.
The FDA approval was based on encouraging data from the phase III HAWK and HARRIER clinical trials, in which Beovu demonstrated non-inferiority compared to Eylea in mean change in best-corrected visual acuity (BCVA) at year one (week 48). Beovu also demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the retina) as early as week 16 and at one year versus Eylea.
Data from both trials showed that at year one, more than half of patients were maintained on the three-month dosing interval (56% in HAWK and 51% in HARRIER).
Novartis’ shares have lost 0.5% in the year so far, in line with the industry’s decline.
Wet AMD is a leading cause of blindness, affecting more than 20 million people worldwide. However, frequent injections are a common reason, due to which patients drop out of the treatment.
Beovu is expected to pose stiff competition to Eylea as it is the first drug to offer less frequent dosing in the first year of therapy while maintaining its effectiveness. The drug’s potential to treat patients with quarterly injections is a major positive and should enable it to capture market share.
The FDA approval of Beovu will strengthen Novartis’ ophthalmology franchise, which comprises Lucentis.
We note that Lucentis is also approved for wet AMD along with macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME), among others.
Novartis has a collaboration agreement with Roche (RHHBY - Free Report) for Lucentis. Roche retains commercial rights for the drug in the United States while Novartis has exclusive commercial rights for the rest of the world.
Approval of new drugs bodes well for Novartis as it looks to strengthen its core pharmaceutical business.
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>